![\"\"](\"https:\/\/www.azuse.cloud\/wp-content\/uploads\/2023\/09\/battling_ptsd_-300x173.jpg\")
<\/p>\n<\/p>\n
Study showed 72% of the people in the MDMA group no longer met the criteria to be diagnosed with PTSD<\/em> A new study published last week suggests the psychedelic drug MDMA, also known as Ecstasy or Molly, can reduce symptoms of post-traumatic stress disorder, and some expect the treatment to be approved by 2024.<\/p>\n The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization that was formed in 1986 and focuses on the medical, legal and cultural contexts for how people can benefit from the “careful” uses of psychedelics and marijuana, sponsored the study.<\/p>\n “Thanks to the combined efforts of dozens of therapists, hundreds of participants who volunteered in MAPS-sponsored trials, and many thousands of generous donors, MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024,” MAPS founder and president Rick Doblin said.<\/p><\/blockquote>\n Fox News<\/a><\/p>\n The potential therapeutic use of MDMA for treating PTSD has been the topic of discussion in the past here:<\/p>\n MDMA Deemed \u201cBreakthrough Therapy\u201d for PTSD<\/a><\/p>\n and here:<\/p>\n MDMA Assisted Therapy for PTSD<\/a><\/p>\n The conversations have been lively. The methodology for the finding seems sound with the Phase 3 caveat pertaining to the test sampling size, between 1000-3000 individuals. Phase 4 monitors long term effects in the general population after approval. The study is published here:<\/p>\n National Library of Medicine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
\nGreg Wehner<\/strong><\/p>\n